findmyKOL

Ryan Massa, MD

Basic profile

University of Pittsburgh

ORCIDNPI
RegionPhiladelphia, PA · NortheastSpecialtyHematology / OncologyFocusOncology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Ryan Massa is an Oncology physician affiliated with University of Pittsburgh. OpenAlex indexes 36 publications with 998 citations (h-index 8).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
36publications

Distinct works indexed by OpenAlex, matched via ORCID.

998citations

Total citations across indexed works.

8h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

51 N 39th Street
Cupp Building 1st Floor
Philadelphia, PA 191042640

Telephone

215-662-9801

Provider last certified this registry record 19 Feb 2025.

View the NPPES registry record

Industry payments

1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    39.8%
    Phenothiazine27.2%
    Prochlorperazine Maleate100%
    Part D23 patients
    Opioid Agonist12.6%
    Oxycodone Hcl100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    35.9%
    Serotonin-3 Receptor Antagonist35.9%
    Ondansetron Hcl100%
    Part D24 patients
  • Cancer & immunology

    12.6%
    Isocitrate Dehydrogenase 1 Inhibitor12.6%
    Tibsovo100%
    Part D<11 patients
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”